Have we Surpassed the Need for Diet & Lifestyle Interventions: A Timeline of Type 2 Diabetes Medications

This blog offers a brief glimpse into the fascinating timeline of scientific discovery behind type 2 diabetes (T2DM) medications. From serendipitous observations to intentional drug design, each breakthrough highlights the remarkable advancements in medical science. Despite these advancements, it's worth considering, have we surpassed the need to make changes to our diet or exercise habits in order to manage T2DM? Read on to learn whether these pharmaceutical innovations have managed to replicate or even surpass the wide-ranging health benefits of a balanced diet and active lifestyle.

Metformin: A Century in the Making

Metformin, one of the oldest and most widely used T2DM medications, traces its roots back to the French lilac (“Galega officinalis”), used in traditional medicine since the 1700s. Scientists discovered that its active compound, guanidine, lowered blood sugar in animals as early as 1918. However, the spotlight on metformin dimmed as insulin gained popularity.

Fast forward to the 1950s: a physician named Jean Sterne revisited metformin’s glucose-lowering properties. After successful clinical trials, metformin became a standard T2DM treatment in Europe in 1958. It took another 37 years for it to be approved in the United States, but today it is considered a first-line therapy for managing T2DM.

Sulfonylureas: From Antibiotics to Diabetes Care

The sulfonylurea story began by accident in the 1940s when doctors noticed that certain sulfonamide antibiotics caused severe low blood sugar in patients. French physiologist August Loubatières confirmed that these compounds stimulated insulin release from the pancreas, making them potential diabetes treatments.

By the 1950s, the first sulfonylureas, such as tolbutamide, were developed. While effective, these medications often caused weight gain and hypoglycaemia, leading to their gradual replacement by newer drugs like metformin. However, they remain a part of the diabetes treatment toolkit for certain cases.

DPP-4 Inhibitors: Precision by Design

DPP-4 inhibitors are a testament to the power of intentional drug design. These medications work by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which rapidly breaks down incretin hormones like GLP-1 and GIP. By preventing this degradation, DPP-4 inhibitors enhance the body’s natural ability to regulate blood sugar.

The first DPP-4 inhibitor, sitagliptin, was approved in 2006, followed by others like saxagliptin and linagliptin. Unlike earlier diabetes medications, DPP-4 inhibitors are known for their safety profile, as they rarely cause hypoglycaemia. These drugs are often used in combination with metformin, providing a complementary approach to managing T2DM.

Incretin-Based Therapies: Inspired by Lizards

In the 1990s, a surprising discovery came from the saliva of the Gila monster, a venomous lizard. Researchers found a compound called exendin-4, which mimics the human hormone GLP-1. GLP-1 stimulates insulin secretion, suppresses appetite, and lowers blood sugar levels.

This discovery led to the development of incretin-based drugs like exenatide (approved in 2005) and later GLP-1 receptor agonists such as liraglutide and semaglutide. These medications not only control blood sugar but also aid in weight loss, offering dual benefits for patients with T2DM. These are now the rock-star weight loss drugs known as Ozempic or Mounjaro.

SGLT2 Inhibitors: A Natural Beginning

The story of SGLT2 inhibitors starts with apple tree bark. In 1835, scientists isolated a compound called phlorizin, which was found to cause glucose excretion through urine. While initially seen as a curiosity, researchers revisited its potential in the 20th century, modifying it to improve its effectiveness and reduce side effects.

By 2012, dapagliflozin (known in Australia as Forxiga) became the first SGLT2 inhibitor approved in Europe, followed by others like canagliflozin and empagliflozin. These drugs not only lower blood sugar but also provide cardiovascular and kidney benefits, revolutionising diabetes care.

Thiazolidinediones: Targeting Insulin Resistance

Thiazolidinediones (TZDs) emerged in the late 20th century as a novel approach to diabetes treatment. Researchers discovered that these drugs improved insulin sensitivity by targeting a receptor called PPAR-gamma. The first TZD, troglitazone, was approved in 1997 but was quickly withdrawn due to safety concerns. Subsequent TZDs like pioglitazone and rosiglitazone followed, offering better safety profiles.

While their use has declined due to concerns about heart failure and other side effects, TZDs highlighted the importance of addressing insulin resistance in T2DM management.

From Discovery to Design: Modern Advances

The development of DPP-4 inhibitors and GLP-1 receptor agonists reflects the transition from serendipitous discoveries to intentional drug design. Scientists now use advanced techniques like molecular modelling to create medications tailored to specific targets, ensuring greater efficacy and safety.

Despite the remarkable discoveries listed above, no medication to date can mimic the broad-ranging benefits of a balanced diet and regular exercise. While medications excel at lowering blood glucose, they cannot address all the health challenges that stem from consistently poor nutrition and inactivity. No one pill or injection can lower your blood glucose levels, blood pressure, cholesterol, improve your mental health, nourish your mind and body, all at the same time.

As a strong proponent of these medications, I appreciate their indispensable role in managing diabetes. However, even the best pharmaceutical advancements should complement, not replace, efforts to maintain good health through lifestyle choices. It’s not an easy path—financial constraints, time pressures, and limited access to good food or facilities, can make lifestyle changes challenging. But we must not surrender our responsibility for health entirely to medication. A combined approach of effective medications and a commitment to healthier living remains the best path to achieving overall well-being.

If you're interested in putting your diabetes into remission, click here to learn more.